ERBB2 and aneurysmal bone cyst: Similarly, in the phase II TBCRC 022 trial, conducted in patients with HER2-positive ABC with brain metastases, the combination of neratinib with capecitabine demonstrated an impressive CNS response rate of 49% [52].